|View printer-friendly version|
|January 28, 2005 9:54 a.m.|
|Teva Announces Court Of Appeals Grants Favorable Ruling On Once-A-Week Version Of Fosamax®|
Jerusalem, Israel, January 28, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the United States Court of Appeals for the Federal Circuit has found that U.S. Patent No. 5,994,329 is invalid and, accordingly, has reversed and vacated an August 2003 ruling by the U.S. District Court in Wilmington, Delaware which had upheld the validity of the patent. The patent is listed in the U.S. Food and Drug Admnistration's Orange Book for Merck & Co.'s Fosamax®, 35 mg and 70 mg, for which Teva has filed an Abbreviated New Drug Application to market a generic version of Fosamax®.